Preexposure Prophylaxis for the Prevention of HIV

Updated guidelines contain few, but important, changes.

Sponsoring Organization: Centers for Disease Control and Prevention (CDC)

Target Audience: Primary care providers, infectious disease specialists, addiction medicine specialists

Background and Objective

The CDC last published guidelines on the use of preexposure prophylaxis (PrEP) in 2014. The new guidelines incorporate updated evidence on the safety and efficacy of PrEP and make changes regarding baseline laboratory evaluation and clinical monitoring.

Key Points

PrEP is indicated for men who have sex with men (MSM), heterosexual individuals, and people who inject drugs (PWID) who have a high risk for HIV infection.
TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) is the only medication recommended for PrEP.
TAF (tenofovir alafenamide) should…

Reviewing Authors

Rajesh T. Gandhi, MD

Disclosures

Grant/Research SupportNIH

Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)

Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)